In an effort to get itself into a place where it can again ship from its FDA-approved plants in India, Ranbaxy Laboratories says it is taking a hard look at how it runs its API operations.
The number of new drug shortages in the U.S. has fallen dramatically during the last few years. Still, the total number of shortages keeps growing, leaving doctors to figure out how to change treatment plans when meds are unavailable.
Novartis' 500 Swiss job cuts announced earlier this month are just the tip of a global iceberg. The company plans to cut or shuffle up to 4,000 jobs in its pharma business, with many of the positions moving to a new operations center in Hyderabad, India, a Swiss newspaper reports.
Japan's Daiichi Sankyo believed it was making a solid move when it bought controlling interest in Ranbaxy Laboratories for $4.6 billion in 2008. Instead it has seen its finances burdened by Ranbaxy's non-stop regulatory issues, leading some to wonder if Daiichi might get fed up and bail out. But executives today said they don't intend to do that, at least not for now. Instead Daiichi will take "drastic" steps to turn the operations around.
The FDA has worked to face down shortages of important, sometimes life-saving, drugs that have sprung up in recent years. But occasionally something as mundane as saline solution can set off a scramble, particularly when the flu season puts added pressure on supplies, leaving hospitals to look for ways to preserve scarce products.
It turns out that Germany will not be the only country facing a shortage of GlaxoSmithKline's chickenpox vaccines. While healthcare providers there have already been given a heads up to prepare for rationing, the company says deliveries worldwide will be affected.
What is a generic drugmaker going to do when the FDA finds flies filling its analytics laboratory and shuts down a yet another plant key to serving the U.S. market? Start looking for other markets. That is what analysts say India's generics leader Ranbaxy Laboratories is faced with now that it has only one FDA-approved facility to work with and its critical API plant is banned from supplying it.
Novartis apparently has job cuts on its January to-do list. After announcing a 500-job shuffle in Switzerland yesterday, the drugmaker now confirms that it will shutter a New York plant that employs 525 people.
Liquid Tamiflu is back. Roche says the temporary shortage of the liquid version of its flu fighter that it warned of two weeks ago is resolved and should stay that way for the rest of flu season.
Merck's Liptruzet has only been on the market since last May, but it will soon be unavailable. The drugmaker is asking wholesalers to return all lots they have because a potential packaging leak could affect its potency.